IndraLab

Statements


| 3

reach
"Germline or somatic mutations and copy number alterations have been identified in several cancers and inactivation of BAP1 accelerates invasion, recurrence and metastases."

reach
"Germline or somatic mutations and deletions of BAP1 have been identified in various tumor types, and downregulation or inactivation of BAP1 could accelerate tumor onset, invasion, recurrence, and metastases ."

reach
"Furthermore, BAP1 has been demonstrated to increase the risk of disease recurrence in patients with resected localized disease: in a cohort of 1479 patients, those with BAP1 loss of function (10.3%) had worse relapse-free survival, even after statistical adjustment for the UISS risk score [49]."